The role of endothelium-derived vasoactive substances in the pathophysiology of exercise intolerance in patients with congestive heart failure

Progress in Cardiovascular Diseases

Volumn 38, Issue 1, 1995, Pages 23-50

  Katz, Stuart D ^a  

^a Department of Medicine Division of Circulatory Physiology Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIUM DERIVED CONSTRICTING FACTOR; ENDOTHELIUM DERIVED RELAXING FACTOR; N(G) NITROARGININE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROSTAGLANDIN; VASOACTIVE AGENT;

CONGESTIVE HEART FAILURE; CORONARY ARTERY BLOOD FLOW; EXERCISE TOLERANCE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEMODYNAMICS; HUMAN; MUSCLE BLOOD FLOW; NONHUMAN; PROSTAGLANDIN SYNTHESIS; PULSATILE FLOW; REVIEW; SHEAR STRESS; VASCULAR ENDOTHELIUM; VASODILATATION;

ANIMAL; DISEASE MODELS, ANIMAL; ENDOTHELINS; EXERCISE TOLERANCE; HEART FAILURE, CONGESTIVE; HEMORHEOLOGY; HUMAN; NITRIC OXIDE; PROSTAGLANDINS; RATS; SUPPORT, NON-U.S. GOV'T;

EID: 0029130295     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0033-0620(05)80012-X     Document Type: Article

References (230)

1. Central and peripheral components of cardiac failure
2. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications
3. Lack of correlation between exercise capacity and indexes of resting left ventricular performance in heart failure
4. A comparison of the effects of vasodilator stimuli on peripheral resistance vessels in normal subjects and in patients with congestive heart failure
5. Regional specificity of peak hyperemic response in patients with congestive heart failure: correlation with peak aerobic capacity
6. Failure to augment maximal blood flow in response to one-leg versus two-leg exercise in patients with congestive heart failure
7. Alterations in vasomotor tone in congestive heart failure
8. Endothelium-derived relaxing factor
9. Regulatory functions of the vascular endothelium
10. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine
11. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor
12. Vascular endothelial cells synthesize nitric oxide from L-arginine
13. L-arginine is a precursor for nitrate biosynthesis in humans
14. Endothelium-derived relaxing and contracting factors
15. Does endothelium-derived nitric oxide have a role in cytokine-induced hypotension?
16. Molecular mechanisms of nitric oxide regulation
17. A novel citrulline-forming enzyme implicated in the formation of nitric oxide by vascular endothelial cells
18. Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme
19. Nitric oxide and endothelins: Novel autocrine/paracrine regulators of the circulation
20. Cytokine-activated endothelial cells express an isotype of nitric oxide synthase which is tetrahydrobiopterin-dependent, calmodulin-independent and inhibited by arginine analogs with a rank-order of potency characteristic of activated macrophages
21. Induction of nitric oxide synthase by cytokines in vascular smooth muscle cells
22. Inducible but not constitutive production of nitric oxide by vascular smooth muscle cells
23. The L-arginine-nitric oxide pathway
24. EDRF coordinates the behavior of vascular resistance vessels
25. Nitric oxide: Physiology, pathophysiology, and pharmacology
26. Superoxide anion is involved in the breakdown of endothelium-derived relaxing factor
27. Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor
28. Mechanisms of nitric oxide release from the vascular endothelium
29. Endothelium-dependent relaxation of coronary arteries by noradrenaline and serotonin
30. L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans
31. Flow-induced release of endothelium-derived relaxing factor
32. Shear stress-induced release of nitric oxide from endothelial cells grow on beads
33. Shear stress elevates endothelial cGMP. Role of a potassium channel and G protein coupling
34. Flow activates an endothelial potassium channel to release an endogenous nitrovasodilator
35. + channels mediate EDRF release to flow but not agonists in rabbit aorta
36. N(G)-Methylarginine, an inhibitor of endothelium-derived nitric oxide synthesis, is a potent pressor agent in the guinea pig; Does nitric oxide regulate blood pressure in vivo?
37. Role of endothelium-derived nitric oxide in the regulation of blood pressure
38. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man
39. Heart failure depresses endothelium-dependent responses in canine femoral artery
40. Systemic vasoconstriction induced by inhibition of nitric oxide synthesis is attenuated in conscious dogs with heart failure
41. Depressed β-adrenergic receptor- and endothelium-mediated vasodilation in conscious dogs with heart failure
42. Defective endothelium-mediated control of coronary circulation in conscious dogs after heart failure
43. Alpha 1-adrenoreceptor activity in arterial smooth muscle following congestive heart failure
44. Endothelium modulation of the effects of nitroglycerin on blood vessels from dogs with pacing-induced heart failure
45. Inhibitory role of the coronary arterial endothelium to alpha-adrenergic stimulation in experimental heart failure
46. Increased production of nitric oxide in coronary arteries during congestive heart failure
47. Diminished endothelium-derived relaxing factor activity in an experimental model of chronic congestive heart failure
48. Temporal evolution of endothelial dysfunction in a rat model of chronic heart failure
49. Increased vascular responsiveness to norepinephrine in rats with heart failure is endothelium dependent. Dissociation of basal and stimulated nitric oxide release
50. Impairment of endothelium dependent responses in a rat model of chronic heart failure: Effects of an exercise training protocol
51. Effects of inhibition of nitric oxide formation on regional blood flow in experimental myocardial infarction
52. Endothelial dysfunction of hind-quarter resistance vessels in experimental heart failure
53. Selective attenuation of endothelium-mediated vasodilation in atherosclerotic human coronary arteries
54. Impaired muscarinic endothelium-dependent relaxation and cyclic guanosine 5′-monophophate formation in atherosclerotic human coronary artery and rabbit aorta
55. Endothelium-dependent dilation of the coronary microvasculature is impaired in dilated cardiomyopathy
56. Endothelium-dependent vasodilation is attenuated in patients with heart failure
57. Impaired endothelium-mediated vasodilation in the peripheral vasculature of patients with congestive heart failure
58. Decreased skeletal muscle vasodilation in patients with congestive heart failure
59. Impaired contraction and relaxation in skin resistance arteries from patients with congestive heart failure
60. Endothelium-dependent forearm vasodilation to acetylcholine but not to substance P is impaired in patients with heart failure
61. Endothelial function in chronic congestive heart failure
62. Resting and exercise-induced release of endothelium-derived nitric oxide is impaired in patients with heart failure
63. Contributions of nitric oxide to basal vasomotor tone in patients with heart failure
64. Enhancement of endothelium-dependent vasodilation by low-dose nitroglycerin in patients with congestive heart failure
65. Modulation of endothelium-dependent responses by chronic alterations in blood flow
66. Effects of norepinephrine on endothelium-dependent vasodilation of forearm resistance vessels
67. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure
68. Increased concentrations of tumour necrosis factor in “cachectic” patients with severe chronic heart failure
69. Anti-EDRF effect of tumor necrosis factor in isolated perfused cat carotid arteries
70. Mediation of cardioprotection by transforming growth factor-β
71. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life
72. G-methyl-L-arginine inhibits tumor necrosis factor-induced hypotension: Implications for the involvement of nitric oxide
73. Nitric oxide synthesis in endothelial cells: evidence for a pathway inducible by TNFα
74. Pathophysiologic correlates of increased serum tumor necrosis factor in patients with congestive heart failure: Relation to nitric oxide-dependent vasodilation in the forearm circulation
75. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic heart failure
76. Effect of local intra-arterial asymmetric dimethlarginine (ADMA) on the forearm arteriolar bed of healthy volunteers
77. Depletion of arterial L-arginine causes reversible tolerance to endothelium-dependent relaxation
78. L-Arginine induced vasodilation in severe heart failure: A marker of endothelial dysfunction?
79. L-arginine evokes both endothelium-dependent and -independent relaxations in L-arginine-depleted aortas of the rat
80. L-arginine-induced hypotension
81. Evaluation of skeletal muscle capillary basement membrane thickness in congestive heart failure
82. Evidence of increased microvascular resistance and arteriolar hyalinosis in skin in congestive heart failure secondary to idiopathic dilated cardiomyopathy
83. Evidence for enhanced free radical activity in chronic congestive heart failure secondary to coronary artery disease
84. Oxygen free radicals in volume overload heart failure
85. Elevated breath pentane in heart failure reduced by free radical scavenger
86. Increased superoxide anion release from human endothelial cells in response to cytokines
87. Rigorous exercise training increases superoxide dismutase activity in ventricular myocardium
88. Effect of ouabain and alteration in potassium concentration on relaxation induced by sodium nitroprusside
89. Effects of Na,K-pump inhibitors and membrane depolarizing agents on acetylcholine-induced endothelium-dependent relaxation and cyclic GMP accumulation in rat aorta
90. Effect of sodium-potassium pump inhibitors and membrane-depolarizing agents on sodium nitroprusside-induced relaxation and cyclic guanosine monophosphate accumulation in rat aorta
91. Potassium-free solution prevents the action but not the release of endothelium-derived relaxing factor
92. Oubain enhances basal release of nitric oxide from carotid artery
93. Interactions between nitroglycerin and endothelium in vascular smooth muscle relaxation
94. Mechanisms underlying the inhibitory interaction between the nitrovasodilator SIN-1 and the endothelium
95. Effect of in vivo nitroglycerin therapy on endothelium-dependent and independent vascular relaxation and cyclic GMP accumulation in rat aorta
96. Studies on vascular smooth muscle tolerance to different cGMP-mediated vasodilators and cross-tolerance to glyceryl trinitrate
97. Tolerance and cross-tolerance between SIN-1 and nitric oxide in bovine coronary arteries
98. Development and mechanism of a specific supersensitivity to nitrovasodilators after inhibition of vascular nitric oxide synthesis in vivo
99. Does antihypertensive therapy improve the function of the vascular endothelium?
100. Effects of chronic captopril therapy on endothelium-derived relaxing factor activity in heart failure
101. Why are converting enzyme inhibitors vasodilators?
102. A novel potent vasoconstrictor peptide produced by vascular endothelial cells
103. Molecular and cellular mechanism of endothelin regulation. Implications for vascular function
104. Endothelin-1 mRNA is widely expressed in porcine and human tissues
105. Inducible endothelin mRNA expression and peptide secretion in cultured human vascular smooth muscle cells
106. Endothelium-derived contracting factors
107. Endothelin: A new cardiovascular regulatory peptide
108. The human endothelin family: Three structurally and pharmacologically distinct isopeptides predicted by three separate genes
109. Endothelin induces potent microvascular constriction
110. Analysis of regional responses to endothelin in hindquarters vascular bed of cats
111. Systemic hemodynamic effects of endothelin in rats
112. Integrated cardiac, renal, and endocrine actions of endothelin
113. Prostacyclin mediates antiaaggregatory and hypotensive actions of endothelin in anaesthetized beagle dogs
114. Cloning and expression of a cDNA encoding an endothelin receptor
115. Cloning and functional expression of a vascular smooth muscle endothelin 1 receptor
116. Endothelium-derived relaxing factor inhibits the endothelin-1-induced increase in protein kinase C activity in rat aorta
117. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor
118. Cloning and functional expression of human cDNA for the ET-B endothelin receptor
119. Tissue distribution and half-life of 125I-Endothelin in the rat Importance of pulmonary clearance
120. Secretory mechanism of immunoreactive endothelin in cultured bovine endothelial cells
121. Fluid flow decreases preproendothelin mRNA levels and suppresses endothelin-1 peptide release in cultured human endothelial cells
122. Raised plasma endothelin-1 concentration following cold pressor test
123. Elevated endothelin-1 in heart failure and loss of normal response to postural change
124. Endothelin has biologic actions at pathophysiological concentrations
125. Effect of endothelin-1 in man
126. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by release of prostacyclin and endothelium-derived relaxing factor
127. Vasodilation induced by endothelin: Role of EDRF and prostanoids in rat hindquarters
128. Endothelin is a potent secretagogue for atrial natriuretic peptide in cultured rat atrial myocytes
129. G-monomethyl arginine inhibits the vasodilating effects of low dose of endothelin-3 on rat mesenteric arteries
130. Increased endothelin in experimental heart failure
131. Endothelin in experimental congestive heart failure in the anesthetized dog
132. Endothelin in thoracic inferior vena caval constriction model of heart failure
133. Influence of congestive heart failure on endothelin levels and receptors in rabbits
134. Renal glomerular endothelin receptors in rats with high-output heart failure
135. Immunoreactive endothelin in human plasma: Marked elevations in patients in cardiogenic shock
136. Plasma endothelin-1 levels in idiopathic dilated cardiomyopathy
137. Plasma endothelin in chronic heart failure
138. Increased plasma concentrations of endothelin in congestive heart failure in humans
139. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure
140. Plasma endothelin concentrations in humans with end-stage heart failure and after heart transplantation
141. Plasma big endothelin-1 concentrations in congestive heart failure patients with or without systemic hypertension
142. Relation between endothelin 1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure
143. Endothelin stimulated by angiotensin II augments contractility of spontaneously hypertensive rat resistance arteries
144. Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist
145. BQ123, an ET-A-receptor antagonist, attenuates hypoxic pulmonary hypertension in rats
146. Physiological significance of endothelin. Its role in congestive heart failure
147. Unchanged plasma concentrations of endothelin-1 in healthy men during short-term infusions of AMP, dDAVP and norepinephrine
148. 2, and prostacyclin
149. Biosynthesis and interaction of endothelium-derived vasoactive mediators
150. Eicosanoids: Prostaglandins, thromboxane, and prostacyclin
151. Arachidonate metabolites and kinins in blood pressure regulation
152. Vascular and renal prostaglandins as counter-regulatory systems in heart failure
153. Flow effects on prostacyclin production by cultured human endothelial cells
154. Prostaglandins mediate arteriole dilation to increased blood flow velocity in skeletal muscle microcirculation
155. Role of endothelium in reactive dilation of skeletal muscle arterioles
156. Role of shear stress and endothelial prostaglandins in flow- and viscosity-induced dilation of arterioles in vitro
157. Arteriolar reactive hyperemia: Modification by inhibitors of prostaglandin synthesis
158. Participation of the prostaglandins in the control of renal blood flow during acute reduction of cardiac output in the dog
159. Prerenal failure: A deleterious shift from renal compensation to decompensation
160. Endothelium-dependent contractions to acetylcholine in the aorta os the spontaneously hypertensive rat
161. Endothelium-dependent responses in carotid and renal arteries of normotensive and hypertensive rats
162. Endothelium-dependent contractions to calcium ionophore A23187, arachadonic acid, and acetylcholine in canine basilar arteries
163. Acute oliguric renal failure induced by indomethacin: Possible mechanisms
164. Prostaglandins in severe congestive heart failure. Relation to activation of the renin-angiotensin system and hyponatremia
165. Impaired acetylcholine-mediated vasodilation in patients with congestive heart failure. Role of endothelium-derived vasodilating and vasoconstricting factors
166. Blood vessel-hormone interaction: Angiotensin, bradykinin, and prostglandins
167. Angiotensin II stimulation of prostaglandin production in cultured human vascular endothelium
168. Interrelations between prostaglandins and vasoconstrictor hormones: contribution to blood pressure regulation
169. Interaction of prostaglandins and angiotensin II in the modulation of renal function in congestive heart failure
170. Myocardial prostaglandin E release by nitroglycerin and modification by indomethacin
171. Interactions between endothelium-derived relaxing and contracting factors in health and cardiovascular disease
172. Prostacyclin releases endothelium-derived relaxing factor and potentiates its action in coronary arteries of the pig
173. Release of endothelin from the porcine aorta. Inhibition by endothelium derived nitrix oxide
174. Hirudin and nitrates inhibit thrombin-induced release of endothelin from the intact porcine aorta
175. Interactions of endothelins and EDRF in bovine native endothelial cells: selective effects of endothelin-3
176. Atrial natriuretic peptide, nitroglycerine, and nitroprusside reduce basal and stimulated endothelin production from cultured endothelial cells
177. Endothelin-3 regulates endothelin-1 production in cultured human endothelial cells
178. Interaction between endothelin-1 and endothelium-derived relaxing factor in human arteries and veins
179. Interaction between endothelium-derived relaxing factor, S-nitrosothiols, and endothelin-1 on calcium mobilization in rat vascular smooth muscle
180. Inhibition of endothelium-derived relaxing factor enhances endothelin-mediated vasoconstriction
181. 1 porcine kidney epithelial cells via formation of an endothelium-derived relaxing factor-like substance
182. Role of endothelium-derived relaxing factor in endothelin-induced vasoconstriction
183. Renal and femoral vascular responses to endothelin-1 in dogs: Role of prostaglandins
184. Endothelins release tissue plasminogen activator and prostanoids
185. The basal and stimulated release of EDRF inhibits the contractions evoked by endothelin-1 and endothelin-3 in aortae of normotensive and spontaneously hypertensive rats
186. Modulation of the vasodepressor actions of acetylcholine, bradykinin, substance P, and endothelin in the rat by a specific inhibitor of nitric oxide formation
187. G-monomethyl-L-arginine does not inhibit the hindquarters vasodilator action of endothelin-1 in conscious rats
188. Negative inotropic effects of cytokines on the heart mediated by nitric oxide
189. Endothelins. Myocardial actions of a new class of cytokines
190. Endothelin-1 induces hypertrophy with enhanced expression of muscle-specific genes in cultured neonatal rat cardiomyocytes
191. Failure of dobutamine to increase exercise capacity despite hemodynamic improvement in severe chronic heart failure
192. Cardiovascular responses to exercise as functions of absolute and relative work load
193. Control of blood flow to dynamically active muscles
194. Local regulation of vascular cross section during changes in femoral arterial blood flow in dogs
195. Reactive dilation of large coronary arteries in conscious dogs
196. Endothelium-dependent flow-induced dilation of canine femoral and saphenous arteries
197. Flow-dependent dilation in a resistance artery still occurs after endothelium removal
198. Crucial role of endothelium in the vasodilator response to increased flow in vivo
199. Enhanced release of endothelium-derived relaxing factor by chronic increases in blood flow
200. + current in vascular endothelial cells
201. Shear stress increases inositol trisphosphate levels in human endothelial cells
202. Flow stimulates endothelial cells to release a nitrovasodilator that is potentiated by reduced thiol
203. Fluid shear stress modulates cytosolic free calcium in vascular endothelial cells
204. Inhibition of adrenergic vasoconstriction by endothelial shear stress
205. Functional hyperemia of skeletal muscle: role of endothelium
206. Endogenous prostaglandins as local regulators of blood flow in man: Effect of indomethacin on reactive and functional hyperemia
207. The contribution of endothelium-derived nitric oxide to exercise-induced vasodilation in man
208. Exercise intolerance in patients with chronic heart failure: role of inpaired nutritive flow to skeletal muscle
209. Active skeletal muscle mass and cardiopulmonary reserve: Failure to attain peak aerobic capacity during maximal exercise in patients with congestive heart failure
210. Exercise training alters endothelium-dependent vasoreactivity of rat abdominal aorta
211. Short-term daily exercise activity enhances endothelial NO synthesis in skeletal muscle arterioles of rats
212. Chronic exercise enhances endothelium-mediated dilation of epicardial coronary artery in conscious dogs
213. Vasodilator responses of coronary resistance arteries of exercise-trained pigs
214. Chronic exercise in dogs increases coronary vascular nitric oxide production and endothelial cell nitric oxide synthase gene expression
215. Endothelium-dependent vasodilation is improved by physical training in normal subjects
216. Exercise training in patients with severe left ventricular dysfunction. Hemodynamic and metabolic effects
217. Controlled trial of physical training in chronic heart failure. Exercise performance, hemodynamics, ventilation, and autonomic function
218. Intense forearm training improves vascular endothelium function in patients with congestive heart failure
219. Functional adaptations of rat skeletal muscle arterioles to aerobic exercise training
220. The emerging concept of vascular remodeling
221. Adaptive regulation of wall shear stress to flow change in the canine carotid artery
222. Endothelial regulation of wall shear stress and blood flow in skeletal muscle microcirculation
223. Reductions in arterial diameter produced by chronic decreases in blood flow are endothelium-dependent
224. Adaptations of carotid arteries of young and mature rabbits to reduced carotid blood flow
225. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells
226. The endothelium as a regulator of vascular smooth muscle proliferation
227. Growth factor activity of endothelin on vascular smooth muscle
228. Determinants of vascular structure
229. Effect of peptide vasoconstrictors on vessel structure